Beginning January 1, 2018, PHMSA requires changes to the random drug testing rate. SIFDA 2 has been updated to reflect the changes.

While the minimum annual random drug testing rate was 25 percent of all covered employees for calendar year 2017, paragraph 49 CFR 199.105(c)(4) requires the Administrator to raise the minimum annual random drug testing rate from 25 percent to 50 percent of all covered employees when the data obtained from the Management Information System (MIS) reports required by §199.119(a) indicate the positive test rate is equal to or greater than 1 percent. In calendar year 2016, the random drug test positive rate was greater than 1 percent.

Therefore, the PHMSA minimum annual random drug testing rate shall be 50 percent of all covered employees for calendar year 2018.

On January 1, 2018 numerous changes to Part 199 became effective affecting our drug and alcohol plan tool.

You will need to regenerate your Written Plan to incorporate these changes.

Changes were made to the following sections:

  • Chapter 1. Definitions
  • Chapter 3. Introduction to Anti-Drug Plan
    • 3.9. Release of Information to Additional Parties
  • Appendix G. Collection Sites, Forms, Equipment and Supplies Used in DOT Urine Collections (Subpart D)
    • §40.45 What form is used to document a DOT urine collection?
  • Appendix J. Problems in Drug Tests (Subpart I)
    • §40.193 What happens when an employee does not provide a sufficient amount of urine for a drug test?
    • §40.199 What problems always cause a drug test to be cancelled?
    • §40.203 What problems cause a drug test to be cancelled unless they are corrected?
    • §40.210 Are drug tests other than urine permitted under the regulations?
  • Appendix K. Substance Abuse Professionals and the Return to Duty Process (Subpart O)
    • §40.281 Who is qualified to act as a SAP?
  • Appendix L. Urine Collection Personnel (Subpart C)
    • §40.33 What training requirements must a collector meet?
    • §40.37 Where is other information on the role of collectors found in this regulation?
  • Appendix M. Medical Review Officers and the Verification Process (Subpart G)
    • §40.121 Who is qualified to act as an MRO?
    • §40.123 What are the MRO’s responsibilities in the DOT drug testing program?
    • §40.135 What does the MRO tell the employee at the beginning of the verification process?
    • §40.137 On what basis does the MRO verify test results involving marijuana, cocaine, amphetamines, semi-synthetic opioids, or PCP?
    • §40.139 On what basis does the MRO verify test results involving 6-acetylmorphine, codeine and morphine?
    • §40.141 How does the MRO obtain information for the verification decision?
    • §40.162 What must MROs do with multiple verified results for the same testing event?
    • §40.169 Where is other information concerning the role of MROs and the verification process found in this regulation?
  • Appendix O. Drug Testing Laboratories (Subpart F)
    • §40.83 How do laboratories process incoming specimens?
    • §40.85 What drugs do laboratories test for?
    • §40.87 What are the cutoff concentrations for drug tests?
    • §40.103 What are the requirements for submitting blind specimens to a laboratory? – REMOVED
    • §40.105 What happens if the laboratory reports a result different from that expected for a blind specimen? – REMOVED
  • Appendix Q. Urine Specimen Collections (Subpart E)
    • §40.67 When and how is a directly observed collection conducted?
  • Appendix U. Training Requirements for STT and BAT (Subpart J)
    • §40.213 What training requirements must STTs and BATs meet?
  • Appendix V. Testing Sites, Forms, Equipment and Supplies Used in Alcohol Testing (Subpart K)
    • §40.225 What form is used for an alcohol test?
    • §40.229 What devices are used to conduct alcohol screening tests?
    • §40.231 What devices are used to conduct alcohol confirmation tests?
    • §40.233 What are the requirements for proper use and care of EBTs?
    • §40.235 What are the requirements for proper use and care of ASDs?
  • Appendix FF. Public Interest Exclusions (Subpart R)
    • §§40.361, 363, 365, 367, 369, 371, 373, 375, 377, 379, 381, 383, 385, 387, 389, 391, 393, 395, 397, 399, 401 – RENUMBERED
    • §40.365 What is the Department’s policy concerning starting a PIE proceeding?
    • §40.401 How does the Department notify employers and the public about a PIE?
  • Appendix GG. Split Specimen Tests (Subpart H)
    • §§40.171, 173, 175, 177, 179, 181, 183, 185, 187 – RENUMBERED
    • §40.189 Where is other information concerning split specimens found in this regulation?
UPCOMING EVENTS